NDI Notifications Are Not Swept Aside As New Drugs – FDA
This article was originally published in The Tan Sheet
FDA’s rejection of PharmaRoth Labs’ Sucanon NDI notifications included a suggestion that the firm try the investigational new drug pathway, but is not a sign of a growing trend at the agency.
You may also be interested in...
Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.
FDA rejects Ovos Natural Health's citizen petition to classify homotaurine as a dietary ingredient, but leaves the door open for future attempts on the pathway Ovos tried to navigate – moving a substance from failed investigational new drug to dietary supplement.
In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.